Tags

Type your tag names separated by a space and hit enter

Efficacious response with lower dose indapamide therapy in the treatment of elderly patients with mild to moderate hypertension.
J Clin Pharmacol. 1995 Jan; 35(1):45-51.JC

Abstract

A low dose (1.25 mg) of indapamide (Lozol, Rhône-Poulenc Rorer Pharmaceuticals, Collegeville, PA) was evaluated in 222 elderly patients (> or = 50 years) with mild to moderate essential hypertension in a multicenter, randomized, double-blind, parallel-group clinical trial. A 4-week single-blind placebo washout period was followed by an 8-week double-blind treatment period. Patients were randomized to receive indapamide 1.25 mg/day or to receive placebo. The primary efficacy variable was the mean change in sitting diastolic blood pressure from baseline to week 8. Eighty-one patients in the indapamide group (73%) and 87 patients in the placebo group (78%) completed the 8 weeks of double-blind therapy. Therapy with 1.25 mg of indapamide produced greater reductions compared with placebo in sitting diastolic blood pressure after 8 weeks of therapy, with statistical significance (P < or = 0.0015) seen after only 2 weeks of therapy and continuing throughout the 8 weeks. All secondary efficacy measures (sitting systolic blood pressure, standing systolic and diastolic blood pressures, and > or = 10 mm Hg decrease or final value of < or = 90 mm Hg in sitting diastolic blood pressure) also showed superior (P < or = 0.0014) improvement in the indapamide group compared with placebo after 8 weeks of double-blind treatment. During the 8-week double-blind treatment period, incidence rates for all adverse events and for drug-related adverse events were similar between the two treatment groups.(

ABSTRACT

TRUNCATED AT 250 WORDS)

Authors+Show Affiliations

University of Miami, Division of Clinical Pharmacology, FL 33136.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

7751412

Citation

Weidler, D, et al. "Efficacious Response With Lower Dose Indapamide Therapy in the Treatment of Elderly Patients With Mild to Moderate Hypertension." Journal of Clinical Pharmacology, vol. 35, no. 1, 1995, pp. 45-51.
Weidler D, Jallad NS, Curry C, et al. Efficacious response with lower dose indapamide therapy in the treatment of elderly patients with mild to moderate hypertension. J Clin Pharmacol. 1995;35(1):45-51.
Weidler, D., Jallad, N. S., Curry, C., Ferdinand, K., Jain, A. K., Schnaper, H. W., Toth, P. D., Codispoti, J., Stokes, A., & McNally, C. (1995). Efficacious response with lower dose indapamide therapy in the treatment of elderly patients with mild to moderate hypertension. Journal of Clinical Pharmacology, 35(1), 45-51.
Weidler D, et al. Efficacious Response With Lower Dose Indapamide Therapy in the Treatment of Elderly Patients With Mild to Moderate Hypertension. J Clin Pharmacol. 1995;35(1):45-51. PubMed PMID: 7751412.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacious response with lower dose indapamide therapy in the treatment of elderly patients with mild to moderate hypertension. AU - Weidler,D, AU - Jallad,N S, AU - Curry,C, AU - Ferdinand,K, AU - Jain,A K, AU - Schnaper,H W, AU - Toth,P D, AU - Codispoti,J, AU - Stokes,A, AU - McNally,C, PY - 1995/1/1/pubmed PY - 1995/1/1/medline PY - 1995/1/1/entrez SP - 45 EP - 51 JF - Journal of clinical pharmacology JO - J Clin Pharmacol VL - 35 IS - 1 N2 - A low dose (1.25 mg) of indapamide (Lozol, Rhône-Poulenc Rorer Pharmaceuticals, Collegeville, PA) was evaluated in 222 elderly patients (> or = 50 years) with mild to moderate essential hypertension in a multicenter, randomized, double-blind, parallel-group clinical trial. A 4-week single-blind placebo washout period was followed by an 8-week double-blind treatment period. Patients were randomized to receive indapamide 1.25 mg/day or to receive placebo. The primary efficacy variable was the mean change in sitting diastolic blood pressure from baseline to week 8. Eighty-one patients in the indapamide group (73%) and 87 patients in the placebo group (78%) completed the 8 weeks of double-blind therapy. Therapy with 1.25 mg of indapamide produced greater reductions compared with placebo in sitting diastolic blood pressure after 8 weeks of therapy, with statistical significance (P < or = 0.0015) seen after only 2 weeks of therapy and continuing throughout the 8 weeks. All secondary efficacy measures (sitting systolic blood pressure, standing systolic and diastolic blood pressures, and > or = 10 mm Hg decrease or final value of < or = 90 mm Hg in sitting diastolic blood pressure) also showed superior (P < or = 0.0014) improvement in the indapamide group compared with placebo after 8 weeks of double-blind treatment. During the 8-week double-blind treatment period, incidence rates for all adverse events and for drug-related adverse events were similar between the two treatment groups.(ABSTRACT TRUNCATED AT 250 WORDS) SN - 0091-2700 UR - https://www.unboundmedicine.com/medline/citation/7751412/Efficacious_response_with_lower_dose_indapamide_therapy_in_the_treatment_of_elderly_patients_with_mild_to_moderate_hypertension. L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&amp;sid=nlm:pubmed&amp;issn=0091-2700&amp;date=1995&amp;volume=35&amp;issue=1&amp;spage=45 DB - PRIME DP - Unbound Medicine ER -